For Immediate Release
Chicago, IL – February 16, 2012 – Zacks.com announces the list
of stocks featured in the Analyst Blog. Every day the Zacks Equity
Research analysts discuss the latest news and events impacting
stocks and the financial markets. Stocks recently featured in the
blog include Charles Schwab Corp.
(SCHW), E*TRADE Financial Corporation (ETFC),
TD Ameritrade Holding Corporation (AMTD),
Amylin Pharmaceuticals, Inc. (AMLN) and
Alkermes plc (ALKS).
Get the most recent insight from Zacks Equity Research with the
free Profit from the Pros newsletter:
http://at.zacks.com/?id=5513
Here are highlights from Wednesday’s Analyst
Blog:
Schwab Reports Rise in DARTs
On Tuesday, Charles Schwab Corp. (SCHW)
released its Monthly Activity Report for January 2012, recording an
increase of 8% in Daily Average Revenue Trades (DARTs) from
December 2011 to 468,400. However, the company’s DARTs declined 8%
year over year. This year-over-year fall in DARTs was mainly
attributable to the absence of a seasonal rise in transactions
involving Schwab Mutual Fund OneSource product.
Schwab registered a fall in new assets, with net inflow of $7.1
billion in January 2012 as against $10.5 billion in December 2011.
However, new assets surged from $6.4 billion recorded in the
prior-year month.
Further, Schwab’s total client assets stood at $1.74 trillion as
of January-end, rising 4% from $1.68 trillion in the prior month
and 9% from $1.59 trillion in the prior-year comparable period. The
company opened 74,000 brokerage accounts in January 2012, slipping
1% from 75,000 in December 2011 but in line with January 2011.
At the end of the reported month, Schwab’s active brokerage
accounts totaled 8.572 million; flat sequentially but up 7% year
over year. Moreover, clients’ banking accounts grew 1% sequentially
and 12% year over year to 787,000 for January. Similarly, the
number of corporate retirement plan participants was 1,504 million,
improving 1% from December 2011 and 3% from January 2011.
Peer Performances
Earlier in the week, E*TRADE Financial
Corporation (ETFC) also recorded a sequential rise in
DARTs. For January 2012, DARTs were 145,390, up 20% sequentially.
However, DARTs fell 20% from the year-ago period due to high market
volatility, which pushed investors to the sidelines.
Similarly, last week, TD Ameritrade Holding
Corporation (AMTD) recorded a sequential rise and
year-over-year fall in DARTs for January 2012. The company’s DARTs
were 374,000, jumping 18% sequentially, but dipping 17% year over
year.
Our Viewpoint
We believe that the optionsXpress deal will likely boost
Schwab’s top line to some extent. While a focus on lower-cost
capital structure will help sustain better results in the upcoming
quarters, the company’s financials will continue to be impacted by
lower trading activity and volatile interest rates. We are also
concerned about the company’s lower degree of capital intensity
relative to its peers.
Schwab currently retains a Zacks #3 Rank, which translates into
a short-term Hold rating. Also, considering the fundamentals, we
maintain a long-term Neutral” recommendation on the stock.
Amylin’s Bydureon Launches in the
U.S.
Amylin Pharmaceuticals, Inc. (AMLN) and
Alkermes plc (ALKS) recently announced the
availability of their type II diabetes treatment, Bydureon
(exenatide once-weekly) in the US.
Bydureon, a glucagon-like peptide-1 (GLP-1) receptor agonist,
gained approval earlier this year as an adjunct to diet and
exercise to improve glycemic control in adults with type II
diabetes. This means that Bydureon can be used as a monotherapy, as
well as in combination with commonly prescribed oral diabetes
therapies.
Approval was granted with a Risk Evaluation and Mitigation
Strategy (REMS) and post-marketing requirements. The REMS will keep
healthcare professionals informed about the risk of acute
pancreatitis and the potential risk of thyroid C-cell tumors
associated with the use of Bydureon, and ensure that the benefits
of Bydureon outweigh these potential risks.
Amylin has been preparing for the US launch of Bydureon. The
company has two commercial units -- one focused on exenatide and
the other on specialty and orphan diseases.
Want more from Zacks Equity Research? Subscribe to the free
Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and
qualitative analysis to help investors know what stocks to buy and
which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives
them keen insights to developments that affect company profits and
stock performance. Recommendations and target prices are six-month
time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides
highlights of the latest analysis from Zacks Equity Research.
Subscribe to this free newsletter today:
http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc.,
which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew
he could find patterns in stock market data that would lead to
superior investment results. Amongst his many accomplishments was
the formation of his proprietary stock picking system; the Zacks
Rank, which continues to outperform the market by nearly a 3 to 1
margin. The best way to unlock the profitable stock recommendations
and market insights of Zacks Investment Research is through our
free daily email newsletter; Profit from the Pros. In short, it's
your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros
at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the
performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an
offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
ALKERMES INC (ALKS): Free Stock Analysis Report
AMYLIN PHARMA (AMLN): Free Stock Analysis Report
TD AMERITRADE (AMTD): Free Stock Analysis Report
E TRADE FINL CP (ETFC): Free Stock Analysis Report
SCHWAB(CHAS) (SCHW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024